Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.
Quantum BioPharma Ltd. has announced an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell Class B Subordinate Voting Shares worth up to $21,225,000. The proceeds from this offering will support clinical studies, research and development, and general corporate purposes. This strategic financial move is expected to bolster Quantum’s operational capabilities and enhance its industry positioning in the biopharmaceutical sector.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, for multiple sclerosis and has licensed a formulation for alcohol consumption effects to Celly Nutrition Corp. Quantum also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.
Average Trading Volume: 3,743
Technical Sentiment Signal: Sell
Current Market Cap: C$64.87M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.